AI+CRO Fusion Innovation: Insilico Medicine Awards Medicilon the "Team Excellence Award" for 2024

2025-01-22

Page View：

Recently, a team from Insilico Medicine (“Insilico”), a global clinical stage biotechnology company powered by generative AI, visited the ChuanSha site of Medicilon in Shanghai. The two parties engaged in an in-depth exchange regarding their business cooperation in 2024. The drug chemistry and ADME team of Insilico expressed their gratitude to Medicilon's DMPK team for their efficient cooperation in handling urgent tasks and presented Medicilon's DMPK team, led by Lei Na and Wang Xinxin, with the "Team Excellence Award" for 2024.

The drug chemistry and ADME team of Insilico expressed their gratitude to Medicilon's DMPK team for their efficient cooperation in handling urgent tasks and presented Medicilon's DMPK team

Empowering AI Drug R&D for High-Quality and Efficient Delivery

Medicilon's DMPK team has continuously empowered Insilico's preclinical project research. They have completed DMPK package studies and non-GLP safety evaluations for multiple oncology projects at the PK and IND application stages. Throughout the cooperation, Medicilon adhered to systematic, stable, and efficient work standards, delivering high-quality research results at the fastest speed. This not only highlighted the team's strong R&D capabilities and relentless pursuit of excellence but also won high recognition from the partners.

The receipt of the "Team Excellence Award" is not only an affirmation of Medicilon's professional capabilities and service quality but also a vivid example of the collaborative innovation and integrated development of AI+CRO in the pharmaceutical industry.

AI+CRO Empowering Drug R&D
Medicilon and Insilico Join Forces

After the award ceremony, the two parties held a conference where they exchanged in-depth discussions on their core strengths and further needs. The Insilico team shared the current status and future trends of AI drug discovery and proposed plans for upcoming research projects. Medicilon focused on sharing the core capabilities and advantages of its team and proposed targeted cooperation plans to support further research projects. Both parties reached a broad consensus on deepening cooperation and efficient empowerment, laying a solid foundation for future smooth exchanges and cooperation.

Currently, the integration of AI and CRO is becoming a core force in driving the transformation of the pharmaceutical industry. Insilico, relying on its proprietary Pharma.AI platform, has efficiently established more than 30 self-research pipelines, with 10 molecules obtaining clinical trial permits. Since 2021, Medicilon has been in a strategic partnership with Insilico, providing consistent, efficient, and stable support for the preclinical research of its projects.

In addition, Medicilon has continuously expanded its business scope according to industry needs. Beyond traditional medicinal chemistry contract research services, it has built an AI drug discovery service platform and a one-stop preclinical service platform for various new modality, including PROTAC, ADC, nucleic acid drugs, bispecific antibodies, peptides, vaccines, and cell and gene therapies, empowering approximately 520 INDs to obtain clinical approval. The cooperation between the two parties exemplifies the practical path of AI+CRO empowering drug R&D.

The recognition from clients is the greatest compliment to Medicilon! Medicilon will use this as an incentive to rely on its one-stop comprehensive preclinical R&D service platform for pharmaceuticals, continue to empower AI drug R&D, and actively explore new applications and models of AI in drug R&D. Medicilon will aim to provide more efficient and high-quality R&D solutions to help global pharmaceutical companies gain a competitive edge and jointly promote the prosperity and development of the pharmaceutical industry.